Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential - Top-Institutions - MDSpire

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential

  • By

  • Michael Colwill

  • Sebastian Povlsen

  • Richard Pollok

  • Kamal Patel

  • James Goodhand

  • Tariq Ahmad

  • Sailish Honap

  • September 16, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Endocrinology
    • Immunology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Metabolic Disease
    • Clinical Research

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Gastroenterology
    • Endocrinology
    • Translational Medicine

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Metabolic Research

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Clinical Trials

Original Source(s)

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential

  • by Michael Colwill, Sebastian Povlsen, Richard Pollok, Kamal Patel, James Goodhand, Tariq Ahmad, Sailish Honap

  • September 16, 2025

Related Content

The innovation trap: How pharma weaponizes a word to extend monopolies

To Fix or Not to Fix: Effect of Gastropexy on Esophageal Manometric Values Post Laparoscopic Sleeve Gastrectomy

Publisher Correction: Machine Learning Models for Predicting Significant Liver Fibrosis in Patients with Severe Obesity and Nonalcoholic Fatty Liver Disease